NCT04161755 — Memorial Sloan Kettering Cancer Center neoantigen vaccine trial
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Registry record
| Registry ID | NCT04161755 ↗ |
|---|---|
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
| Collaborators | Genentech, Inc., Massachusetts Institute of Technology |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Pancreatic Cancer |
| Enrollment | 29 participants (target) |
| Start date | 2019-12-13 |
| Primary completion | 2026-11-11 (est.) |
| Last registry update | 7 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04161755), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04161755?
NCT04161755 (Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery) is registered on ClinicalTrials.gov as Phase 1, sponsored by Memorial Sloan Kettering Cancer Center.
Is NCT04161755 recruiting?
As of the 2026-01-07 registry update, NCT04161755 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04161755?
The lead sponsor is Memorial Sloan Kettering Cancer Center. Collaborators: Genentech, Inc., Massachusetts Institute of Technology.
What condition does NCT04161755 study?
The registered condition is Pancreatic Cancer. Primary completion is listed as 2026-11-11 (estimated).
Are results available for NCT04161755?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04161755.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.